--- title: "AstraZeneca COPD drug shows trial success, sales forecast raised" publication: "MediaBias News" url: "https://mediabias.news/health/astrazeneca-copd-drug-shows-trial-success-sales-forecast-raised" api: "https://mediabias.news/api/v1/stories/astrazeneca-copd-drug-shows-trial-success-sales-forecast-raised" markdown: "https://mediabias.news/health/astrazeneca-copd-drug-shows-trial-success-sales-forecast-raised.md" audio: "https://mediabias.news/api/audio/astrazeneca-copd-drug-shows-trial-success-sales-forecast-raised" category: "Health" published: "2026-09-08T12:05:16.499Z" source_reported: "2026-09-08T11:45:17.000Z" updated: "2026-09-08T12:15:07.600Z" trust_score: 60 critic_score: 65 hype_score: 41 assessment_type: "coverage-and-source-reporting-analysis" fact_check_status: "not-performed" coverage_measured: "2026-09-08T12:39:44.293Z" --- # AstraZeneca COPD drug shows trial success, sales forecast raised *New data on tozorakimab suggests it could significantly reduce flare-ups in patients with chronic obstructive pulmonary disease.* **Scores for the source reporting** (0-100, assessing the original journalism this article was written from, not this write-up): - Trust 60 of 100, higher is better. Central claim attributed to named body, with figures and origins stated, but relies on anonymous sourcing for some details. - Craft 65 of 100, higher is better. Quotes affected parties and names what is still unknown, but lacks a clear statement of why the story matters. - Hype 41 of 100, lower is better. Headline promises blockbuster potential, but the body details the drug's specific efficacy and market positioning. Scored by MediaBias News; method at https://mediabias.news/methodology. **The short version** - AstraZeneca's experimental drug tozorakimab has shown success in two late-stage trials for chronic obstructive pulmonary disease (COPD). - The drug reduced moderate to severe COPD flare-ups by 23% to 43% in different patient groups compared to a placebo. - AstraZeneca has increased its projected peak annual sales for tozorakimab to more than $5 billion. - US approval for the drug is anticipated in the first quarter of 2027, with the FDA currently reviewing it. AstraZeneca has published the full results from two successful late-stage clinical trials for its experimental drug, tozorakimab, intended for the treatment of chronic obstructive pulmonary disease (COPD). The drug, which targets the protein IL-33 that drives inflammation and mucus production, demonstrated a reduction in moderate and severe COPD flare-ups across various patient subsets. These results have bolstered the company's sales expectations for the drug. In the trials, tozorakimab helped reduce moderate and severe flare-ups by between 23% and 43% when compared to a placebo, depending on the patient group. The company reported that the drug reduced flare-ups by 29% and 34% in former smokers with moderate and severe conditions, respectively. In a broader population of current and former smokers, reductions were 30% and 29%. The drug is currently under priority review by the US Food and Drug Administration, with an expected approval in the first quarter of 2027. AstraZeneca has raised its forecast for the drug's peak annual sales to more than $5 billion, contributing to its broader revenue target of $80 billion by 2030. The company believes tozorakimab has the potential to reach a large number of COPD patients who are currently underserved by existing biologic treatments. ## Disagreement on specific reduction figures Reports differ on the exact percentage reductions in flare-ups. CNBC reported that the drug reduced moderate and severe flare-ups by 23% in patients with a blood eosinophil count below 150, by 34% in those with a count at or above 150, and by 43% in those at or above 300. The verified claims stated that the drug helped reduce moderate and severe COPD flare-ups by 23% to 43% in various patient subsets compared to placebo. ## What the coverage left out None of the left-rated reports mention the specific figures for the reduction in moderate and severe flare-ups in former smokers, which were reported as 29% and 34% respectively. The left-rated reports also do not detail the specific figures for the reduction in moderate and severe flare-ups in the larger overall population of current and former smokers, which were 30% and 29% respectively. ## Who covered it Shares of the 6 covering outlets with a published leaning rating: - Left: 17% (1) - Centre: 83% (5) - Right: 0% (0) 2 of 8 covering outlets carried no usable leaning rating and were excluded from those percentages. Coverage measured 2026-09-08T12:39:44.293Z. **Coverage watch:** developing. Checked 5 times; 1 check found a material change. Most recently checked 2026-09-08T13:15:07.813Z. ## How the sides framed it ### Left - The left-rated report from CNBC highlighted the successful late-stage trial results for AstraZeneca's COPD drug, tozorakimab, and the company's increased sales forecast. It detailed the drug's mechanism of action, blocking the IL-33 protein to reduce inflammation and mucus production. The report included quotes from AstraZeneca executives, including CEO Pascal Soriot, discussing the drug's potential to capture a broad patient group due to significant unmet need and underuse of biologics in COPD compared to asthma. It also noted the drug's performance across different patient groups, including those with low eosinophil counts, for whom current biologic treatments are limited. The article mentioned the drug is under FDA priority review with an expected US approval in early 2027. ### Centre - All three centre‑rated outlets reported that AstraZeneca’s experimental COPD medicine, referred to as Tozo or Tozorakimab, achieved a reduction in disease flare‑ups in late‑stage trials. The digests note statistically significant and clinically meaningful benefits across a broad patient population, and that the results were published in a leading medical journal and presented at a European conference. - Bloomberg’s digest highlighted the drug’s impact on flare‑up rates and its potential as a blockbuster product. Market Screener’s summary specified the OBERON and TITANIA Phase III studies, emphasized the statistical significance of the exacerbation reduction and noted benefit across blood eosinophil levels. STAT’s brief pointed to the treatment’s competitiveness with other emerging COPD therapies and its capacity to reach a larger patient base. - None of the centre digests included any information on the drug’s projected price, sales forecast, regulatory approval timeline, or patient‑access programmes. They also did not quote external clinicians, industry analysts, or patient organisations, leaving those perspectives absent from the coverage. ### Right No separate framing summary. ## Factuality profile of the covering outlets These are published factuality ratings of the outlets, not a verdict on whether this story or its claims are true. - high: 4 - unknown: 3 - veryHigh: 1 ## Verification scope This page compares coverage and scores the source reporting. It is not a ClaimReview verdict on whether the underlying event or claim is true. ## Original reporting this was written from - [Bloomberg](https://bloomberg.com/news/articles/2026-09-08/astrazeneca-s-lung-disease-drug-shows-broad-benefit-in-trials) — AstraZeneca’s Lung Disease Drug Shows Broad Benefit in Trials - [Business Wire](https://businesswire.com/news/home/20260908211444/en/Tozorakimab-demonstrated-statistically-significant-and-highly-clinically-meaningful-reduction-in-COPD-exacerbations-in-OBERON-and-TITANIA-Phase-III-trials) — Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials - [Joplin Globe](https://joplinglobe.com/region/national_business/tozorakimab-demonstrated-statistically-significant-and-highly-clinically-meaningful-reduction-in-copd-exacerbations-in-oberon-and/article_0f2455d8-3fbd-5159-9bca-427f3008fefc.html) — Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials - [Market Screener](https://marketscreener.com/news/astrazeneca-tozorakimab-demonstrated-statistically-significant-and-highly-clinically-meaningful-re-ce785bd8dd80f022) — AstraZeneca : Tozorakimab demonstrated statistically significant and highly clinically meaningful reduction in COPD exacerbations in OBERON and TITANIA Phase III trials - [CNBC](https://cnbc.com/2026/09/08/astrazeneca-copd-drug-tozorakimab-shows-positive-late-stage-trial-results.html) — AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes - [BizToc](https://biztoc.com/x/9f1e1fe0df699433) — AstraZeneca's COPD drug scores two late-stage trial wins as full data boosts blockbuster hopes - [STAT](https://statnews.com/2026/09/08/astrazeneca-tozorakimab-copd-exacerbations-titania-oberon) — AstraZeneca’s experimental COPD treatment posts strong results in late-stage studies - [Pharmaphorum](https://pharmaphorum.com/news/it-turns-out-copd-may-be-laughing-matter-after-all) — It turns out COPD may be a laughing matter after all ## Questions **What is tozorakimab and what does it do?** Tozorakimab is an experimental drug developed by AstraZeneca for chronic obstructive pulmonary disease (COPD). It works by blocking a protein called IL-33, which is known to drive inflammation and mucus production in the airways, aiming to reduce the frequency and severity of COPD flare-ups. **How effective were the trial results for tozorakimab?** In late-stage trials, tozorakimab reduced moderate and severe COPD flare-ups by 23% to 43% in various patient groups compared to a placebo. These results have increased confidence in the drug's potential as a significant treatment for the condition. **What is AstraZeneca's sales forecast for tozorakimab?** Following the positive trial results, AstraZeneca has raised its peak annual sales forecast for tozorakimab to more than $5 billion. This projection contributes to the company's overall revenue goals and highlights the perceived market potential for the drug. **When might tozorakimab be approved in the US?** The drug is currently under priority review by the US Food and Drug Administration. AstraZeneca anticipates that US approval for tozorakimab could be granted in the first quarter of 2027. --- MediaBias News — https://mediabias.news. Reproduced from https://mediabias.news/health/astrazeneca-copd-drug-shows-trial-success-sales-forecast-raised. Please cite as: MediaBias News, "AstraZeneca COPD drug shows trial success, sales forecast raised", https://mediabias.news/health/astrazeneca-copd-drug-shows-trial-success-sales-forecast-raised